HK1090044A1 - 雜芳基取代的 -二氫吲哚- -酮衍生物及包含其的藥劑 - Google Patents

雜芳基取代的 -二氫吲哚- -酮衍生物及包含其的藥劑

Info

Publication number
HK1090044A1
HK1090044A1 HK06110531.9A HK06110531A HK1090044A1 HK 1090044 A1 HK1090044 A1 HK 1090044A1 HK 06110531 A HK06110531 A HK 06110531A HK 1090044 A1 HK1090044 A1 HK 1090044A1
Authority
HK
Hong Kong
Prior art keywords
dihydroindol
heteroaryl
derivatives
substituted
medicaments containing
Prior art date
Application number
HK06110531.9A
Other languages
English (en)
Inventor
Wilfried Lubisch
Wilfried Hornberger
Thorsten K Oost
Daryl Richard Sauer
Liliane Unger
Wolfgang Wernet
Herv Geneste
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of HK1090044A1 publication Critical patent/HK1090044A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK06110531.9A 2003-09-30 2006-09-21 雜芳基取代的 -二氫吲哚- -酮衍生物及包含其的藥劑 HK1090044A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/675,300 US20050070718A1 (en) 2003-09-30 2003-09-30 Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
PCT/EP2004/010940 WO2005030755A1 (en) 2003-09-30 2004-09-30 Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them

Publications (1)

Publication Number Publication Date
HK1090044A1 true HK1090044A1 (zh) 2006-12-15

Family

ID=34377107

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06110531.9A HK1090044A1 (zh) 2003-09-30 2006-09-21 雜芳基取代的 -二氫吲哚- -酮衍生物及包含其的藥劑

Country Status (15)

Country Link
US (4) US20050070718A1 (zh)
EP (4) EP2546251A1 (zh)
JP (3) JP4684229B2 (zh)
CA (1) CA2537598C (zh)
CY (1) CY1116730T1 (zh)
DK (1) DK1667993T3 (zh)
ES (1) ES2547642T3 (zh)
HK (1) HK1090044A1 (zh)
HR (1) HRP20151025T1 (zh)
HU (1) HUE025419T2 (zh)
MX (1) MXPA06003558A (zh)
PL (1) PL1667993T3 (zh)
SI (1) SI1667993T1 (zh)
TW (1) TW200526640A (zh)
WO (1) WO2005030755A1 (zh)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827604B1 (fr) * 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
EP1831197A2 (de) * 2004-12-31 2007-09-12 Abbott GmbH & Co. KG Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
US8030499B2 (en) * 2005-01-28 2011-10-04 Taisho Pharmaceutical Co., Ltd. 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
DE102005014936A1 (de) * 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014904A1 (de) * 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005015957A1 (de) * 2005-03-31 2006-10-05 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
WO2006100082A2 (de) * 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
KR20080053297A (ko) * 2005-08-11 2008-06-12 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유종 트랜스막 전도도 조정자의 조절자
WO2007052517A1 (ja) * 2005-10-31 2007-05-10 Sumitomo Chemical Company, Limited ヒドロキシ－２－ピロリジンカルボキシアミド化合物の製法
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
WO2007063123A1 (de) 2005-12-02 2007-06-07 Abbott Gmbh & Co. Kg Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2869945C (en) 2006-04-07 2018-01-23 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2008025736A1 (en) 2006-08-26 2008-03-06 Abbott Gmbh & Co. Kg Substituted benzimidazolone derivatives, medicaments comprising them and their use
DE102006040915A1 (de) 2006-08-26 2008-03-20 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
WO2008080972A1 (en) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Substituted oxindole derivative and its use as a vasopressin receptor modulator
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2008080971A1 (en) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Substituted oxindole derivative and its use as a vasopressin receptor ligand
PT2114921E (pt) * 2006-12-30 2013-03-26 Abbott Gmbh & Co Kg Derivado de oxindol substituído e sua utilização como ligante do recetor de vasopressina
US8486931B2 (en) * 2007-03-02 2013-07-16 Abbott Gmbh & Co. Kg Substituted oxindole compounds
EP2789606B1 (en) 2007-05-09 2017-11-15 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
WO2009071691A2 (de) * 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Oxindol-derivate und ihre verwendung als medikament
US8703774B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
RU2484090C2 (ru) * 2007-12-07 2013-06-10 Эбботт Гмбх Унд Ко.Кг 5-галогензамещенные производные оксиндола и их применение для лечения вазопрессинзависимых заболеваний
MX2010006204A (es) 2007-12-07 2011-03-16 Abbott Gmbh & Co Kg Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
NZ612635A (en) * 2007-12-07 2015-06-26 Vertex Pharma Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2231643B1 (de) 2007-12-07 2012-10-31 Abbott GmbH & Co. KG Amidomethyl-substitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
CN106146469A (zh) * 2007-12-27 2016-11-23 Abbvie德国有限责任两合公司 取代的羟吲哚衍生物及其用于治疗加压素依赖性疾病的应用
FR2927625B1 (fr) * 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
CA2931134C (en) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
FR2941946B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
FR2941947B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
WO2010142739A1 (en) * 2009-06-10 2010-12-16 Abbott Gmbh & Co. Kg Use of substituted oxindole derivatives for the treatment and prophylaxis of pain
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
ES2858351T3 (es) 2010-04-22 2021-09-30 Vertex Pharma Compuesto intermedio para proceso de producción de compuestos de cicloalquilcaraboxamido-indol
DK2623499T3 (da) 2010-10-01 2015-06-08 Taisho Pharmaceutical Co Ltd 1,2,4-triazolonderivat
MX2013006694A (es) 2010-12-21 2013-07-29 Bayer Ip Gmbh Procedimiento para producir oxindoles sustituidos con triazinilo.
CN103380127B (zh) 2010-12-21 2016-08-10 拜耳知识产权有限责任公司 制备n-磺酰基取代的羟吲哚的方法
BR112014009927B1 (pt) 2011-10-27 2022-07-05 Taisho Pharmaceutical Co., Ltd Derivado de azol, composição farmacêutica que o compreende e uso do mesmo
CA2852991C (en) 2011-11-08 2019-12-31 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
SG11201406182PA (en) 2012-03-30 2014-10-30 Taisho Pharmaceutical Co Ltd Fused azole derivative
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
EP2970229B1 (en) 2013-03-14 2017-02-08 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
AR095327A1 (es) 2013-03-14 2015-10-07 Abbvie Deutschland Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
US9862704B2 (en) 2013-12-20 2018-01-09 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases
WO2015091931A1 (en) 2013-12-20 2015-06-25 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
MX369857B (es) * 2014-02-14 2019-11-25 Takeda Pharmaceuticals Co Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
RU2744460C2 (ru) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
US9527856B2 (en) 2014-05-15 2016-12-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases
SG11201703963QA (en) 2014-11-18 2017-06-29 Vertex Pharma Process of conducting high throughput testing high performance liquid chromatography
US10046318B2 (en) 2014-12-19 2018-08-14 Dow Silicones Corporation Ligand components, associated reaction products, activated reaction products, hydrosilylation catalysts and hydrosilylation curable compositions including the ligand components, and associated methods for preparing same
MA53105A (fr) 2018-07-03 2021-05-12 Univ Illinois Activateurs de la réponse à une protéine non dépliée

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805536B1 (fr) 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
FR2810320B1 (fr) 2000-06-19 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2827604B1 (fr) * 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
DE102004033834A1 (de) 2004-07-13 2006-02-02 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
US8030499B2 (en) 2005-01-28 2011-10-04 Taisho Pharmaceutical Co., Ltd. 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
DE102005014904A1 (de) 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
WO2006100082A2 (de) 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
EP1667993A1 (en) 2006-06-14
US20050070718A1 (en) 2005-03-31
CA2537598C (en) 2010-03-09
PL1667993T3 (pl) 2015-12-31
TW200526640A (en) 2005-08-16
HUE025419T2 (en) 2016-02-29
JP4684229B2 (ja) 2011-05-18
JP2007507456A (ja) 2007-03-29
WO2005030755A1 (en) 2005-04-07
DK1667993T3 (en) 2015-10-05
CY1116730T1 (el) 2017-03-15
EP1667993B1 (en) 2015-07-01
US7902379B2 (en) 2011-03-08
MXPA06003558A (es) 2006-08-31
EP2546251A1 (en) 2013-01-16
EP2546250A1 (en) 2013-01-16
JP2011102294A (ja) 2011-05-26
US20070185126A1 (en) 2007-08-09
SI1667993T1 (sl) 2015-11-30
HRP20151025T1 (hr) 2015-11-06
ES2547642T3 (es) 2015-10-07
JP2011088894A (ja) 2011-05-06
US20110071156A1 (en) 2011-03-24
EP2546252A1 (en) 2013-01-16
US20070021607A1 (en) 2007-01-25
CA2537598A1 (en) 2005-04-07
US8350055B2 (en) 2013-01-08

Similar Documents

Publication Publication Date Title
HK1090044A1 (zh) 雜芳基取代的 -二氫吲哚- -酮衍生物及包含其的藥劑
IL176005A0 (en) 2,6-bisheteroaryl-4-aminopyrimidine derivatives and pharmaceutical compositions containing the same
HK1084123A1 (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
HK1080482A1 (en) Novel thiophenylglycoside derivatives, methods forproduction thereof, medicaments comprising said c ompounds and use thereof
HK1084124A1 (en) Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof
HK1090368A1 (en) 2,3,6-trisubstituted-4-pyrimidone derivatives
IL162548A0 (en) 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same
IL166482A0 (en) Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same
IL163117A (en) Indazole derivatives and pharmaceutical compositions containing the same
HK1082744A1 (en) Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
EP1577317A4 (en) NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, MEDICINAL COMPOSITIONS COMPRISING SAID DERIVATIVES AND MEDICAL USE OF SAID DERIVATIVES
IL172159A0 (en) 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same
EP1617807A4 (en) SUBSTITUTED 1,4-DIAZEPINE AND ITS USES
HK1081554A1 (en) Indoline derivatives substituted in position 6, production and use thereof as medicaments
IL174479A (en) The derivatives of myastrin, pharmaceutical preparations containing them and their uses
IL164424A0 (en) Novel perindopril, salt and pharmaceutical compositions containing same
IL166821A0 (en) Novel 1,4-diazabicycloalkane derivatives their preparation and use
EP1539675A4 (en) ARYL AND HETEROARYLPROPENAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC APPLICATIONS THEREOF
PL394604A1 (pl) Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna
MXPA03000644A (es) Nuevos derivados de indol y uso como medicamentos.
IL181216A0 (en) 3, 5-seco-4-norcholestane derivatives and pharmaceutical compositions containing the same
HUP0303155A3 (en) 2-thio-substituted imidazole derivatives, the use thereof and pharmaceutical compositions containing them
ZA200309513B (en) Novel heterocyclic derivatives and medicinal use thereof.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190929